Vivelle-Dot
Vivelle-Dot is a twice-weekly transdermal estradiol patch, known for its small size and multiple dose strengths suited to fine-tuning estradiol levels.
How it works
Vivelle-Dot is a twice-weekly estradiol patch distinguished by its small surface area compared to other patches — which reduces skin contact and can improve tolerability for people with skin sensitivity. Like all transdermal estradiol, it bypasses liver first-pass metabolism. The twice-weekly change schedule (typically Mondays and Thursdays, or another consistent pairing) provides more frequent estradiol delivery events than weekly patches, which can smooth out any end-of-cycle level dips. Multiple dose strengths are available, making it practical for incremental dose adjustments.
For people with a uterus, Vivelle-Dot must be used with a progestogen. Application is typically to the lower abdomen or buttocks; the smaller patch size reduces the need for large, irritation-free surface areas. As with all patches, sites should be rotated to minimize cumulative skin irritation.
How to track Vivelle-Dot
- Hot flash frequency and severity — the primary indicator of whether estradiol levels are therapeutically adequate.
- Twice-weekly change day adherence — consistency matters more with twice-weekly patches because there are more change events per month.
- Skin reactions at specific application sites — the smaller patch size may reduce irritation, but rotation is still important.
- Night sweats and sleep quality as secondary response measures.
- Breast tenderness or bloating — the main indicators of dose overshoot.
- Use a consistent two-day-of-week schedule (e.g., Monday/Thursday) and log each change — with twice-weekly dosing, inconsistent timing can cause detectable symptom fluctuations.
- Rotate among three to four sites and log each — even the smaller Vivelle-Dot patch causes cumulative skin irritation if always applied to the same spot.
- Track the days between change days specifically — any hot flash spikes in the 24 hours before a change are a sign of end-of-cycle level drop that your physician should know about.
- Log breast tenderness and bloating carefully alongside dose information — they are the clearest early signal that a dose may be higher than needed.
- When your dose is adjusted, mark the exact date and track the following four weeks separately — changes to transdermal estradiol take two to four weeks to fully stabilize.
Questions to ask your physician
- My log shows hot flash increases in the [hours/day] before my twice-weekly change. Does the frequency and timing suggest my dose needs adjustment, or just tighter scheduling?
- My pre-treatment baseline was [X] hot flashes per day. At [N] weeks on Vivelle-Dot, my current weekly average is [Y]. Is that trajectory appropriate for this dose?
- I've been logging breast tenderness since [date] — here is the pattern relative to my change days. Does that suggest dose overshoot?
- I've been tracking skin irritation at [specific sites] — the pattern is [description]. Given the smaller patch size, is this level of irritation expected, or should I switch sites?